NCT Number: NCT01706016
Local Treatment by Thermic Destruction of Primitive Breast Cancer
Demonstrate the effectiveness of laser in the treatment of cancerous lesions by determinating with histological analysis of the specimen the percentage of tumor cells remaining in the area treated by the laser
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year–80 year
Sex eligibility
Female
Study type
Interventional
Phase
Phase 2
Primary location
Centre Oscar Lambret, Lille, Nord, France
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Noninflammatory unilateral and unifocal breast cancer
- Size </= 20mm (ultrasound measure)
- Histological confirmation of cancer by biopsy grade status hormone and HER2.
- Good delineation of the lesion on ultrasound.
- Minimum distance of 5 mm between the tumor and the skin between the tumor and muscle.
- Age between 18 and 80
- ECOG performance status 0 or 1
Treatment and study plan
Primary outcomes
-
Effectiveness of laser treatment
Time frame: 28 days after initial diagnosis
Destruction of the carcinoma will be assess by histological analysis of the specimen.
If more than 10% of viables cancerous cells are remaining in the volume treated by laser, the procedure would be a fail
Secondary outcomes
-
Life quality
Time frame: D-0 and before the surgery
Life quality will be assess using the questionnaire QLQ-C30 breast module BR23-version 3
Sponsors and collaborators
Lead sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Other
Registry information
Official study title
Local Treatment by Thermic Destruction of Primitive Breast Cancer. Phase II: Feasibility and Effectiveness, Standardization of Procedures.
Acronym: LASERBREAST1
Important dates
- Study start
- 2012
- Primary completion
- 2016
- Study completion
- 2016
- First posted
- Oct 15, 2012
- Registry last updated
- Mar 29, 2018
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer
NCT03387553
Breast Cancer, Breast Cancer Female
Tampa, Florida, United States
View Trial DetailsRemoval of the Ovaries/Fallopian Tubes and CA-125 Screening to Reduce the Risk of Ovarian Cancer in Women at Increased Genetic Risk
NCT00043472
Adnexal Diseases, Breast Cancer
Bethesda, Maryland, United States
View Trial DetailsG1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer
NCT03455270
Adenocarcinoma, Advanced Breast Cancer
Beverly Hills, California, United States
View Trial DetailsWide Spectrum Micronutrients Supplementation in Patients With Cancer Related Fatigue During Neoadjuvant and Adjuvant Chemotherapy
NCT06137833
Breast Cancer, Breast Diseases
Brescia, BRESCIA, Italy
View Trial Details